Skip to main content

Table 4 Baseline patient characteristics

From: Impact of patient education on chronic heart failure in primary care (ETIC): a cluster randomised trial

 

Intervention (n = 115)

Control (n = 126)

P-value

Gender male, n (%)

69 (60)

80 (63.5)

0.58

Age (years), mean (SD)

74.7 (10.3)

73.5 (10.8)

0.42

Chronic heart failure duration, median (IQR)

5 (1–11)

5 (2–10)

0.66

EF mean (SD)

50.9 (13.2)

47.7 (15.2)

0.16

HFpEF n (%)

93 (80.9)

94 (74.6)

0.24

NYHA stage, n (%)

 I

14 (12.2)

25 (19.8)

 

 II

69 (60)

67 (53.2)

0.26

 III

32 (27.8)

34 (27)

 

Current smoker, n (%)

14 (12.2)

25 (19.8)

0.11

BMI kg/m2, n (%)a

 < 25

25 (22.2)

44 (35.8)

 

 25–30

44 (38.9)

52 (42.3)

0.008

 ≥ 30

44 (38.9)

27 (21.9)

 

Hypertension, n (%)

72 (62.6)

65 (51.6)

0.08

Type 2 diabetes, n (%)

30 (26.1)

22 (17.5)

0.10

Hypercholesterolaemia, n (%)

50 (43.5)

54 (42.9)

0.92

COPD, n (%)

9 (7.8)

19 (15.1)

0.08

SF-36 mental health score, mean (SD)

60.3 (21.2)

60.1 (21.3)

0.89

SF-36 physical health score, mean (SD)

52.1 (22.5)

50.9 (22.1)

0.66

MLHFQ score, mean (SD)b

29.1 (22.1)

24.4 (21.7)

0.07

 <24

50 (52.6)

64 (57.7)

 

 24–45

22 (23.2)

26 (23.4)

0.64

 >45

23 (24.2)

21 (18.9)

 

Patient adherencec, n (%)

 Good adherence

46 (44.2)

49 (43)

 

 Minor nonadherence

56 (53.9)

60 (52.6)

0.67

 Nonadherence

2 (1.9)

5 (4.4)

 
 

Intervention (n = 102)

Control (n = 121)

P-value

Treatment, n (%)e

98 (96.1)

117 (96.7)

1.00

β-blocker

63 (61.8)

73 (60.3)

0.83

ACE inhibitor

51 (50)

65 (53.7)

0.58

ARB

34 (33.3)

29 (24)

0.12

ACE inhibitor or ARBd

85 (83.3)

93 (76.9)

0.23

β-blocker and (ACE inhibitor or ARB)

56 (54.9)

60 (49.6)

0.43

Thiazide diuretics

12 (12.6)

16 (13.2)

0.74

Loop diuretics

71 (69.6)

78 (64.5)

0.42

Thiazide diuretics or loop diuretics

76 (74.5)

90 (74.3)

0.98

Mineralocorticoid receptor antagonists

15 (14.7)

21 (17.4)

0.59

Digoxin

11 (10.8)

10 (8.3)

0.52

  1. ACE inhibitor angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, COPD chronic obstructive pulmonary disease, HFpEF heart failure with preserved ejection fraction, EF ejection fraction, SD standard deviation
  2. a n = 5 missing data for body mass index. bQuestionnaires with more than three missing responses were excluded (n = 35: 15 in the Control Group and 20 in the Intervention Group). c n = 23 missing data for adherence. dOne patient had angiotensin-converting enzyme inhibitor and angiotensin receptor blocker
  3. e18 patients had missing data concerning treatments at baseline
  4. Significant P-value are in bold